BioCentury | May 8, 2020
Product Development

May 7 Quick Takes: Gaboxadol meets in Phase II for Fragile X; plus Innovent, Lilly, Tetraphase and more

...single to low double digits based on annual net sales. China approves Canbridge’s NDA for Puma’s...
...therapy. Canbridge has rights to Nerlynx in mainland China, Taiwan, Hong Kong and Macau from Puma...
...SGLT2 - Sodium-glucose cotransporter 2 BioCentury Staff Nerlynx (Brand), PB272 (Compound #), HKI-272 (Compound #), Oral neratinib (Generic) Puma...
BioCentury | Feb 19, 2020
Finance

Eyeing IPO, Canbridge raises $98M to advance, commercialize products

...The company holds Chinese rights to Caphosol from EUSA Pharma Ltd. and exclusive rights from Puma...
BioCentury | Nov 6, 2019
Company News

Nov. 5 Company Quick Takes: Takeda licenses MD Anderson CAR NK cell portfolio; plus Myriad, Canbridge, BioCryst-Torii and Strongbridge

...with trastuzumab. Canbridge, which has rights to the inhibitor of EGFR, HER2 and HER4 from Puma...
BioCentury | Oct 21, 2019
Clinical News

Seattle Genetics at all-time high on strength of breast cancer readout

...Seattle Genetics believes will give tucatinib an improved safety profile. On Oct. 8, shares of Puma...
...after an analyst downgrade based on competitive risk from tucatinib, citing the candidate’s tolerability profile. Puma’s...
...under FDA review in combination with capecitabine to treat HER2-positive disease in a third-line setting. Puma...
BioCentury | Oct 8, 2019
Company News

Oct. 8 Company Quick Takes: Novartis’ anti-VEGF approved for AMD; plus Merck-4D, Acorda, Clinuvel and Puma

...gained European approval in the indication in 2014. Puma shares slide after downgrade Shares of Puma...
...sell and cut his price target to $8 from $24. Choi described competitive risk to Puma’s...
...and Jonathan Block, Associate Editor brolucizumab (RTH258, esba1008) Scenesse, afamelanotide (CUV1647, melanotan, EPT1647 implant) Novartis AG Merck & Co. Inc. Puma...
BioCentury | Sep 11, 2019
Company News

Sept. 11 Company Quick Takes: Glaxo to buy Sitari; plus Aimmune, Xeris, Puma and United Therapeutics

...two and up. Gvoke is the company’s first commercial product. FDA to review Nerlynx sNDA Puma...
...for its drug Nerlynx neratinib in combination with capecitabine to treat HER2-positive metastatic breast cancer. Puma...
...company, Mundipharma International Ltd. (Dublin, Ireland). BioCentury Staff GlaxoSmithKline plc Aimmune Therapeutics Inc. Xeris Pharmaceuticals Inc. Purdue Pharma L.P. United Therapeutics Corp. Puma...
BioCentury | May 16, 2019
Clinical News

May 16 ASCO Quick Takes: Aduro ends MM trial; plus Puma, PharmaMar, Genocea, J&J

...is a humanized IgG4 mAb targeting TNFSF13. Nerlynx improves PFS by 24% in breast cancer Puma...
...Generic) Zepsyre, lurbinectedin (PM01183, PM1183, tryptamicidin) Aduro Biotech Inc. American Society of Clinical Oncology ASCO Genocea Biosciences Inc. Johnson & Johnson PharmaMar S.A. Puma...
BioCentury | May 9, 2019
Company News

May 9 Company Quick Takes: Chimerix, Puma, Janssen

..."Brincidofovir Fails to Improve Survival in Adenovirus Study" ). Puma reports declining sales of Nerlynx Puma...
BioCentury | Apr 26, 2019
Product Development

Rise of the independents, biotechs go to market

...last five years. While some therapies, such as cancer drugs Rubraca and Nerlynx neratinib from Puma...
...Cambridge, U.K. IQVIA Holdings Inc. (NYSE:IQV), Durham, N.C. Neurocrine Biosciences Inc. (NASDAQ:NBIX), San Diego, Calif. Puma...
BioCentury | Apr 5, 2019
Company News

Pierre Fabre gets European, African rights to Puma's Nerlynx

...Pierre Fabre will pay $60 million up front for commercialization rights to Puma's Nerlynx neratinib in...
...neratinib in Europe, excluding Russia and Ukraine, and in certain North and West African countries. Puma...
...cancer within one year of completion of prior adjuvant Herceptin trastuzumab-based therapy (see "EC Approves Puma's...
Items per page:
1 - 10 of 209